FindTrial
Sign In

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-004504-39-DE
Enrollment
56
Registered
2007-04-24
Start date
2008-06-24
Completion date
Unknown
Last updated
2013-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 14.0 Level: PT Classification code 10017758 Term: Gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: XELODA 500mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Capecitabine CAS Number: 154361-50-9 Current Sponsor code: Capecitabin Concentration unit: mg milligram(s) Concent

Sponsors

Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 56 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Germany

Contacts

Public ContactKKS Halle

Koordinierungszentrum für Klinische Studien

info@kks-halle.de+493455574907

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026